Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of CytomX Therapeutics, Inc. The shares are listed on the NASDAQ Global Select Market under the symbol “CTMX.”

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Amy Tu and Ali DeGolia. The tax team included partner Rachel D. Kleinberg. Partner David R. Bauer and associates Bonnie Chen and Elizabeth R. Diggs provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post